GENZYME LAUNCHES KEY TEST TO MONITOR GLEEVEC RESISTANCE
Genzyme Corporation announced today the availability of an important new test
to monitor drug resistance in chronic myeloid leukemia (CML) patients who are
treated with Gleevec (imatinib mesylate). Despite high response rates to Gleevec,
approximately four to five percent of patients who were initially treated successfully
will develop resistance during therapy. Genzyme's new BCR-ABL Mutation Analysis
test will assist physicians in evaluating resistance to therapy and facilitate
appropriate adjustments to treatment.